Last reviewed · How we verify
Lispro Mixture Therapy
Lispro Mixture is a combination of rapid-acting insulin lispro and intermediate-acting insulin lispro protamine suspension that mimics physiologic insulin secretion by providing both mealtime and basal insulin coverage.
Lispro Mixture is a combination of rapid-acting insulin lispro and intermediate-acting insulin lispro protamine suspension that mimics the body's natural insulin secretion pattern to control blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus requiring insulin therapy.
At a glance
| Generic name | Lispro Mixture Therapy |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | Insulin combination therapy |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Lispro Mixture combines two formulations of insulin lispro: the rapid-acting component addresses postprandial (after-meal) glucose spikes, while the protamine-complexed intermediate-acting component provides basal insulin coverage between meals and overnight. This dual-action approach approximates the body's natural biphasic insulin response to maintain glycemic control throughout the day.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL) (PHASE3)
- Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients (PHASE2, PHASE3)
- Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy (PHASE4)
- Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia (PHASE4)
- Exenatide for Stress Hyperglycemia (PHASE2, PHASE3)
- Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes (PHASE4)
- A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes (PHASE3)
- Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |